Tiziana Life Sciences Ltd: A Plain-English Investor Guide

This guide helps you understand Tiziana Life Sciences’ performance over the past year. We will break down the company’s status so you can decide if it fits your investment goals.

1. What does this company do?

Tiziana is a research-focused biotech firm. They do not sell products yet. Instead, they focus on high-stakes clinical trials for their lead drug, Foralumab.

Most drugs require injections and cause side effects. Tiziana is testing Foralumab as a nasal spray. They believe this method is safer and better at calming an overactive immune system. This could help treat Multiple Sclerosis (MS), Alzheimer’s, and Multiple System Atrophy (MSA). Because they are in the clinical stage, they produce trial data rather than commercial medicine.

2. How did they perform this year?

Tiziana is currently in a heavy spending phase. Since they have no products on the market, they generate no sales revenue.

• Rising Costs: In 2025, the company spent $12.9 million in cash to run the business, up from $1.5 million in 2024. This jump covers the costs of managing clinical trials and meeting government regulations.
• The Bottom Line: The company reported a $18.4 million loss for 2025, compared to an $11.9 million loss in 2024. These losses come from research, development, and administrative costs.
• Small Team: By the end of 2025, the company had only 10 full-time employees. They rely on outside contractors to run their clinical trials.

3. Financial Health: The "Cash Crunch"

Tiziana burns through cash to fund its research. They keep the lights on by selling more shares of the company.

• Fundraising: In 2025, they raised $10.06 million by selling shares. They have an "At-the-Market" program that allows them to sell up to $100 million in stock whenever they need cash.
• Dilution: Every time they sell new shares, your ownership percentage shrinks. This is a reality for early-stage biotech investors, as the company must issue more stock to cover its operating losses.

4. Risks and Realities

• The "All-In" Bet: The company’s future depends entirely on Foralumab. If these trials fail, the company’s value could collapse.
• Corporate Governance: Because Tiziana is based in Bermuda, they follow different rules than U.S. companies.
  • Limited Legal Recourse: You generally cannot file class-action lawsuits. Your options to sue for poor management are very limited.
  • Concentrated Power: Gabriele Cerrone controls roughly 35% of the company. He exerts significant influence over corporate strategy.
  • The "Success Fee": A company controlled by Mr. Cerrone receives a 3.5% to 9% fee if Tiziana is sold. This creates a potential conflict of interest during a buyout.
  • Tax Hurdles: The company does not provide the data U.S. investors need to avoid "PFIC" tax penalties. These penalties can be costly, so consult a tax professional.

5. Future Outlook

Tiziana is a high-risk, high-reward startup. They will likely keep selling shares to fund their trials. Investors should note that the company offers fewer protections than a typical U.S. stock. The company’s survival depends on its ability to raise more cash until they can sell or license their drug.

Investor Takeaway: Before investing, ask yourself if you are comfortable with the risks of a company that has no revenue, relies on constant share dilution, and operates under a governance structure that offers limited protection to minority shareholders. If you choose to proceed, ensure you have consulted with a tax professional regarding the potential PFIC status of your investment.